Alam Kamran’s Feb. 4 Sell‑to‑Cover: Cash Flow Move, Not a Warning for Taysha Gene Therapies
Alam Kamran’s Feb. 4 sell‑to‑cover at Taysha Gene Therapies: routine tax‑planning or liquidity buildup? Understand how insider moves could fund TSHA‑102’s Phase II rollout.
5 minutes to read